COMAPC thanks Representative Faith Gilbert and the Sanofi Genzyme Company for providing the inflatable prostate cancer model used at the golf tournament. COMAPC strongly believes that raising awareness about prostate cancer through education is a key to improving the lives of men. We encourage conversations between men and their health care providers to determine screening, diagnosis and treatment. The inflatable model educates by showing diagrams of anatomical placement of the prostate gland in the body as well as showing the progression of prostate cancer in easy to understand terms.

After Congressmen Dennis Kucinich (D-OH), Dan Burton (R-IN) and Don Young (R-AK) organized a bipartisan group of 44 Members of Congress to object to a recommendation by the United States Preventative Task Force (USPTF) that healthy men should not receive a blood test to screen for prostate cancer, Health and Human Services Secretary Kathleen Sibelius agreed to overrule the recommendation.

UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk

About the Prostate Cancer Foundation (PCF): PCF is the world's leading philanthropic organization funding and accelerating prostate cancer research. Founded in 1993, PCF has raised more than $720 million and provided funding to more than 2,000 research programs at nearly 200 cancer centers and universities. The PCF global research enterprise now extends to 19 countires. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transfomrational cancer research. Its efforts have helped produce a 20-fold increase in govenment funding for prostate cancer. For more information, visit www.pcf.org.

Six teams of scientists at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are each receiving two-year, $100,000 Pelotonia Research Awards to fund “high-risk, high-reward” research projects involving blood, breast, liver, prostate and skin cancers.  Click here to read more.

Doses of a neurotransmitter might offer a way to boost the effectiveness of anticancer drugs and radiation therapy, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.  Click here to read more.

A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival time of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo.

Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone.

Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva (denosumab) delayed the spread of cancer to the bones. These results were recently published in The Lancet, and were previously presented at the 2011 European Multidisciplinary Cancer Conference.  Click here to read more.